Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
ANÉMIE – NOVINKY Z KONGRESU EHA©
15 septembra, 2020 7:11 pmV Amsterdame sa v dňoch 13. – 16. júna 2019 uskutočnilo stretnutie viac ako 12 000 hematológov a iných odborníkov na 24. ročníku kongresu...
PET AFTER 2 CYCLES OF ABVD IN PATIENTS WITH EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA TREATED WITHIN THE PHASE 3 GHSG HD16 STUDY
15 septembra, 2020 7:11 pmAuthor(s): Michael Fuchs, Helen Goergen, Carsten Kobe, et. al. EHA Library. Fuchs M. Jun 15, 2019; 267402; S819 Abstract:...
FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
15 septembra, 2020 7:11 pmAuthor(s): Alessandra Tedeschi, Jan Burger, Paul M. Barr, et. al. EHA Library. Tedeschi A. Jun 14, 2019; 267308; S107 ...
THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL
15 septembra, 2020 7:11 pmAuthor(s): Enrico Tiacci, Luca De Carolis, Edoardo Simonetti, et. al. EHA Library. Tiacci E. Jun 14, 2019; 267305; S104 ...
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL – A LYSA TRIAL
15 septembra, 2020 7:11 pmAuthor(s): S Legouill, Asma Beldi-Ferchiou, Victoria Cacheux, et. al. EHA Library. Le Gouill S. Jun 14, 2019; 267304; S103 ...
BLINATUMOMAB FOR MINIMAL RESIDUAL DISEASE (MRD) IN ADULTS WITH BCELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCPALL): MEDIAN OVERALL SURVIVAL (OS) NOT REACHED AT 5 YEARS FOR COMPLETE MRD RESPONDERS
15 septembra, 2020 7:11 pmAuthor(s): Nicola Goekbuget, Hervé Dombret, Gerhard Zugmaier, et. al. EHA Library. Goekbuget N. Jun 16, 2019; 267373; S1619 Abstract:...
Cílená terapie a léčebné režimy u chronické lymfocytární leukemie a maligních lymfomů
15 septembra, 2020 7:11 pmLetošní 24. kongres Evropské hematologické společnosti se v oblasti léčby chronické lymfocytární leukemie zaměřil na cílenou terapii a v řadě sdělení na léčebné...
A RANDOMIZED, DOUBLE BLIND PHASE 2 STUDY OF 3 DIFFERENT DOSES OF PRM-151 IN PATIENTS WITH MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH OR INELIGIBLE FOR RUXOLITINIB
15 septembra, 2020 7:11 pmAuthor(s): Srdan Verstovsek, Moshe Talpaz, Martha Wadleigh, et. al. EHA Library. Verstovsek S. Jun 15, 2019; 267411; S828 Abstract:...
RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS
15 septembra, 2020 7:11 pmAuthor(s): Naveen Pemmaraju, Haris Ali, Vikas Gupta EHA Library. Pemmaraju N. Jun 14, 2019; 266467; PF668 Abstract: PF668 ...
MOLECULAR ANALYSIS IN MAJIC PV CORRELATION WITH CLINICAL ENDPOINTS
15 septembra, 2020 7:11 pmAuthor(s): Natalia Curto-Garcia, Joanna Baxter, Erica Harris, et. al. EHA Library. Curto-Garcia N. Jun 16, 2019; 267361; S1607 Abstract:...